⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1767674 | 1.00 | — | — | |
| SCHEMBL2513584 | 1.00 | — | — | |
| SCHEMBL10363675 | 1.00 | — | — | |
| SCHEMBL24013 | 0.87 | — | — | |
| SCHEMBL1144188 | 0.87 | — | — | |
| SCHEMBL25407819 | 0.87 | — | — | |
| SCHEMBL17688345 | 0.87 | — | — | |
| SCHEMBL21351608 | 0.87 | — | — | |
| SCHEMBL17688346 | 0.87 | — | — | |
| SCHEMBL348275 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 609 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11993566-B2 | Hydroformylation method | LG CHEM, LTD. (KR) | 2024-05-28 | — | — | US | claimed |
| WO-2023130006-A1 | SILYLATING GRAFTING AGENTS, POLYMERS GRAFTED THEREWITH AND METHODS OF SYNTHESIS | BRIDGESTONE CORPORATION (JP) | 2023-07-06 | — | — | WO | claimed |
| US-20230167139-A1 | PHOTOCHROMIC GERMOLE-FUSED DIARYLETHENES AND PRODUCTION THEREOF | THE UNIVERSITY OF HONG KONG (CN) | 2023-06-01 | — | — | US | claimed |
| EP-4006007-A1 | HYDROFORMYLATION METHOD | LG Chem, Ltd. (KR) | 2022-06-01 | — | — | EP | claimed |
| WO-2017044043-A1 | PROCESS FOR DIRECT AMIDATION OF AMINES VIA RH(I)-CATALYZED ADDITION OF BOROXINES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-03-16 | — | — | WO | claimed |
| US-20140161764-A1 | Compositions and Methods to Attract the Brown Marmorated Stink Bug (BMSB), Halyomorpha halys | UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 2014-06-12 | — | — | US | claimed |
| WO-2013090703-A1 | COMPOSITIONS AND METHODS TO ATTRACT THE BROWN MARMORATED STINK BUG (BMSB), HALYOMORPHA HALYS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 2013-06-20 | — | — | WO | claimed |
| EP-1926776-B1 | USE OF A RUBBER COMPOUND AS A MATERIAL IN THE INSERTION AREA OF FUEL CELLS | FREUDENBERG CARL KG (DE) | 2012-11-14 | — | — | EP | claimed |
| EP-1938407-B1 | USE OF A ELASTOMER BLEND AS A MATERIAL IN THE INSERTION AREA OF THE FUEL CELLS | FREUDENBERG CARL KG (DE) | 2010-11-17 | — | — | EP | claimed |
| US-7714053-B2 | Rubber compound | CARL FREUDENBERG KG (DE) | 2010-05-11 | — | — | US | claimed |
| EP-1926774-B1 | ELASTOMER BLEND | FREUDENBERG CARL KG (DE) | 2009-12-23 | — | — | EP | claimed |
| US-20080315148-A1 | Rubber Compound | CARL FREUDENBERG KG (DE) | 2008-12-25 | — | — | US | claimed |
| US-7468459-B2 | Process for the preparation of chiral beta amino acid derivatives by asymmetric hydrogenation | MERCK & CO., INC. (US) | 2008-12-23 | — | — | US | claimed |
| EP-1606243-B1 | PROCESS FOR THE PREAPAATION OF CHIRAL BETA AMINO ACID DERIVATIVES BY ASYMMETRIC HYDROGENATION | MERCK & CO INC (US) | 2008-07-09 | — | — | EP | claimed |
| EP-1856028-A1 | PROCESS TO CHIRAL BETA AMINO ACID DERIVATIVES BY ASYMMETRIC HYDROGENATION | Merck & Co., Inc. (US) | 2007-11-21 | — | — | EP | claimed |
| US-20060194977-A1 | Process for the preparation of chiral beta amino acid derivatives by asymmetric hydrogenation | MERCK SHARP & DOHME LLC | 2006-08-31 | — | — | US | claimed |
| WO-2006081151-A1 | PROCESS TO CHIRAL BETA AMINO ACID DERIVATIVES BY ASYMMETRIC HYDROGENATION | MERCK & CO., INC. (US) | 2006-08-03 | — | — | WO | claimed |
| EP-1606243-A1 | PROCESS FOR THE PREAPAATION OF CHIRAL BETA AMINO ACID DERIVATIVES BY ASYMMETRIC HYDROGENATION | Merck & Co. Inc. (US) | 2005-12-21 | — | — | EP | claimed |
| WO-2004085378-A1 | PROCESS FOR THE PREPARATION OF CHIRAL BETA AMINO ACID DERIVATIVES BY ASYMMETRIC HYDROGENATION | MERCK & CO. INC. (US) | 2004-10-07 | — | — | WO | claimed |
| US-20240228482-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | HOTSPOT THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| EP-3143026-B1 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | NOVARTIS AG (CH) | 2024-07-10 | — | — | EP | disclosed |
| US-20240217991-A1 | COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS | GENZYME CORPORATION (US) | 2024-07-04 | — | — | US | disclosed |
| EP-4384519-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | Albert-Ludwigs-Universität Freiburg (DE) | 2024-06-19 | — | — | EP | disclosed |
| US-12012426-B2 | Tetradentate diaminodiphosphine ligand and transition metal complex, and method for manufacturing same and application for same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2024-06-18 | — | — | US | disclosed |
| WO-2024110573-A1 | CROSSLINKED POLYSILAZANE AND COMPOSITION COMPRISING THE SAME | MERCK PATENT GMBH (DE) | 2024-05-30 | — | — | WO | disclosed |
| WO-2024112692-A1 | CASITAS B-LINEAGE LYMPHOMA PROTOONCOGENE B (CBL-B) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| US-11993566-B2 | Hydroformylation method | LG CHEM, LTD. (KR) | 2024-05-28 | — | — | US | disclosed |
| WO-2024105563-A1 | SUBSTITUTED BICYCLIC PYRIDONE DERIVATIVES | PFIZER INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024097598-A1 | TRIAZINES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 | MERCK SHARP & DOHME LLC (US) | 2024-05-10 | — | — | WO | disclosed |
| EP-4364737-A2 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2024-05-08 | — | — | EP | disclosed |
| EP-4364804-A2 | INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | Janssen Pharmaceutica NV (BE) | 2024-05-08 | — | — | EP | disclosed |
| US-11976057-B2 | MrgX2 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-05-07 | — | — | US | disclosed |
| US-20240124408-A1 | Substituted Cyclohexanecarboxamides, Their Preparation and Their Therapeutic Application | SANOFI (FR) | 2024-04-18 | — | — | US | disclosed |
| WO-2024074977-A1 | SUBSTITUTED 1 H-PYRAZOLO-PYRIDINE AND-PYRIMIDINE COMPOUNDS | PFIZER INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024076674-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| EP-4229056-B1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-3538526-B1 | CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-3782996-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-04-10 | — | — | EP | disclosed |
| US-20240109871-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-04-04 | — | — | US | disclosed |
| US-20240109888-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-04-04 | — | — | US | disclosed |
| EP-4339184-A1 | ALKYL CARBOXYLIC ACID COMPOUNDS AND APPLICATION THEREOF | Medshine Discovery Inc. (CN) | 2024-03-20 | — | — | EP | disclosed |
| US-11919908-B2 | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2024-03-05 | — | — | US | disclosed |
| EP-3915994-B9 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | NOVARTIS AG (CH) | 2024-02-28 | — | — | EP | disclosed |
| US-11897900-B2 | Inhibitors of KEAP1-Nrf2 protein-protein interaction | JANSSEN PHARMACEUTICA NV (BE) | 2024-02-13 | — | — | US | disclosed |
| WO-2024030960-A2 | COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS | Kojin Therapeutics, Inc. (US) | 2024-02-08 | — | — | WO | disclosed |
| US-11884661-B2 | 3-substituted propionic acids as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-30 | — | — | US | disclosed |
| US-20240018103-A1 | 3-HYDROXYOXINDOLE DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC. (JP) | 2024-01-18 | — | — | US | disclosed |
| US-20240018126-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-01-18 | — | — | US | disclosed |
| EP-3833662-B1 | INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-17 | — | — | EP | disclosed |
| WO-2024010794-A1 | ANTI-VIRAL COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| EP-3532197-B1 | CYCLIC SUPPORTED CATALYSTS | UNIV PARIS SACLAY (FR) | 2024-01-10 | — | — | EP | disclosed |
| US-20240002397-A1 | 3-AMINO PYRROLIDINE AND PIPERIDINE MACROCYCLIC OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-01-04 | — | — | US | disclosed |
| EP-4299123-A2 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | Novartis AG (CH) | 2024-01-03 | — | — | EP | disclosed |
| US-11851422-B2 | Anti-viral compounds | ALIGOS THERAPEUTICS, INC. | 2023-12-26 | — | — | US | disclosed |
| EP-4288428-A1 | AMIDES AS CBL-B INHIBITORS | Genentech, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-3915994-B1 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | NOVARTIS AG (CH) | 2023-11-22 | — | — | EP | disclosed |
| US-20230365580-A1 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | disclosed |
| WO-2023210741-A1 | BENZOTRIAZOLE COMPOUND | 第一三共株式会社 | 2023-11-02 | — | — | WO | disclosed |
| EP-4263493-A1 | SUBSTITUTED CYCLOHEXANECARBOXAMIDES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | Sanofi (FR) | 2023-10-25 | — | — | EP | disclosed |
| EP-4247801-A1 | 3-AMINO PYRROLIDINE AND PIPERIDINE MACROCYCLIC OREXIN RECEPTOR AGONISTS | Merck Sharp & Dohme LLC (US) | 2023-09-27 | — | — | EP | disclosed |
| US-11767322-B2 | Triazolopyridinyl compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-09-26 | — | — | US | disclosed |
| US-11760744-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11753416-B2 | Compounds and compositions for inducing chondrogenesis | NOVARTIS AG (CH) | 2023-09-12 | — | — | US | disclosed |
| EP-4229056-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3891154-B1 | 5-HYDROXY-7-OXABICYCLO[2.2.1]HEPTANE-2-CARBOXAMIDE DERIVATIVES FOR INDUCING CHONDROGENESIS FOR TREATING JOINT DAMAGE | NOVARTIS AG (CH) | 2023-08-16 | — | — | EP | disclosed |
| EP-4225746-A1 | MRGX2 ANTAGONISTS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2023-08-16 | — | — | EP | disclosed |
| WO-2023150394-A1 | METHODS FOR TREATMENT OF CANCER | FRONTIER MEDICINES CORPORATION (US) | 2023-08-10 | — | — | WO | disclosed |
| EP-4222142-A1 | 3-HYDROXYOXINDOLE DERIVATIVES AS CRHR2 ANTAGONIST | RaQualia Pharma Inc. (JP) | 2023-08-09 | — | — | EP | disclosed |
| US-20230242471-A1 | THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230219983-A1 | TETRADENTATE DIAMINODIPHOSPHINE LIGAND AND TRANSITION METAL COMPLEX, AND METHOD FOR MANUFACTURING SAME AND APPLICATION FOR SAME | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2023-07-13 | — | — | US | disclosed |
| US-20230212139-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-07-06 | — | — | US | disclosed |
| WO-2023130006-A1 | SILYLATING GRAFTING AGENTS, POLYMERS GRAFTED THEREWITH AND METHODS OF SYNTHESIS | BRIDGESTONE CORPORATION (JP) | 2023-07-06 | — | — | WO | disclosed |
| US-20230212170-A1 | INHIBITORS OF KRAS G12C PROTEIN AND USES THEREOF | ANTENGENE DISCOVERY LIMITED (CN) | 2023-07-06 | — | — | US | disclosed |
| WO-2023130005-A1 | COMPOSITIONS INCLUDING FUNCTIONALIZED SILYLATED POLYMERS, CURED COMPOSITIONS AND METHODS | BRIDGESTONE CORPORATION (JP) | 2023-07-06 | — | — | WO | disclosed |
| US-11681219-B2 | Resist composition | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2023-06-20 | — | — | US | disclosed |
| US-20230167139-A1 | PHOTOCHROMIC GERMOLE-FUSED DIARYLETHENES AND PRODUCTION THEREOF | THE UNIVERSITY OF HONG KONG (CN) | 2023-06-01 | — | — | US | disclosed |
| WO-2023077040-A1 | RXFP1 AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-04 | — | — | WO | disclosed |
| US-11639362-B2 | Tetradentate diaminodiphosphine ligand and transition metal complex, and method for manufacturing same and application for same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2023-05-02 | — | — | US | disclosed |
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-02 | — | — | US | disclosed |
| EP-4168384-A1 | THYROMIMETICS | Autobahn Therapeutics, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20230112980-A1 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | NOVARTIS AG (CH) | 2023-04-13 | — | — | US | disclosed |
| US-20230097678-A1 | NEW MACROCYCLIC COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2023-03-30 | — | — | US | disclosed |
| US-20230093249-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-03-23 | — | — | US | disclosed |
| WO-2023017152-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2023-02-16 | — | — | WO | disclosed |
| US-20230047296-A1 | Nrf2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-02-16 | — | — | US | disclosed |
| US-11548865-B2 | 2-azaspiro[3.4]octane derivatives as M4 agonists | NOVARTIS AG (CH) | 2023-01-10 | — | — | US | disclosed |
| US-20230002345-A1 | FUSED RING COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-01-05 | — | — | US | disclosed |
| US-20230002293-A1 | RADIOHALOGEN PROSTHETIC MOIETIES AND RADIOLABELED BIOMOLECULES | UNIV DUKE (US) | 2023-01-05 | — | — | US | disclosed |
| EP-4110776-A1 | NEW MACROCYCLIC COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Les Laboratoires Servier (FR) | 2023-01-04 | — | — | EP | disclosed |
| US-20220396588-A1 | COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS | GENZYME CORPORATION (US) | 2022-12-15 | — | — | US | disclosed |
| US-20220387395-A1 | UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION | NURIX THERAPEUTICS, INC. | 2022-12-08 | — | — | US | disclosed |
| US-11518763-B2 | Macrocyclic compound and use thereof | SCOHIA PHARMA, INC. (JP) | 2022-12-06 | — | — | US | disclosed |
| US-20220213108-A1 | DEAZAGUAINE COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION | 2022-07-07 | — | — | US | disclosed |
| WO-2022140231-A1 | DEAZAGUAINE COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION (US) | 2022-06-30 | — | — | WO | disclosed |
| EP-3679021-B1 | 6-CHROMANOL DERIVATIVES AND THEIR SYNTHESIS | DSM IP ASSETS BV (NL) | 2022-06-29 | — | — | EP | disclosed |
| EP-3750896-B1 | CHIRAL TETRADENTATE LIGAND, METHOD FOR PRODUCING SAME AND TRANSITION METAL COMPLEX OF SAID CHIRAL TETRADENTATE LIGAND | TAKASAGO PERFUMERY CO LTD (JP) | 2022-06-29 | — | — | EP | disclosed |
| WO-2022133027-A1 | SUBSTITUTED CYCLOHEXANECARBOXAMIDES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2022-06-23 | — | — | WO | disclosed |
| EP-3538525-B1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-06-22 | — | — | EP | disclosed |
| US-20220185793-A1 | COMPOUNDS FOR THE TREATMENT OF ONCOVIRUS INDUCED CANCER AND METHODS OF USE THEREOF | CELLESTIA BIOTECH AG (CH) | 2022-06-16 | — | — | US | disclosed |
| US-20220169642-A1 | COMPOUNDS FOR THE TREATMENT OF ONCOVIRUS INDUCED CANCER AND METHODS OF USE THEREOF | CELLESTIA BIOTECH AG (CH) | 2022-06-02 | — | — | US | disclosed |
| EP-4006007-A1 | HYDROFORMYLATION METHOD | LG Chem, Ltd. (KR) | 2022-06-01 | — | — | EP | disclosed |
| EP-4003965-A1 | UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION | Nurix Therapeutics, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| WO-2022109117-A1 | 3-AMINO PYRROLIDINE AND PIPERIDINE MACROCYCLIC OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-05-27 | — | — | WO | disclosed |
| US-20220153733-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2022-05-19 | — | — | US | disclosed |
| US-20220135412-A1 | LOW-TEMPERATURE FORMATION OF GROUP 13-15 CERAMICS AND GROUP 13-15-16 CERAMICS | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | 2022-05-05 | — | — | US | disclosed |
| WO-2022086828-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-04-28 | — | — | WO | disclosed |
| US-20220119388-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2022-04-21 | — | — | US | disclosed |
| US-20220119391-A1 | MACROCYCLIC COMPOUND AND USE THEREOF | SCOHIA PHARMA, INC. (JP) | 2022-04-21 | — | — | US | disclosed |
| WO-2022071484-A1 | 3-HYDROXYOXINDOLE DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC. (JP) | 2022-04-07 | — | — | WO | disclosed |
| EP-3766878-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-03-16 | — | — | EP | disclosed |
| US-11274108-B2 | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | GENZYME CORPORATION (US) | 2022-03-15 | — | — | US | disclosed |
| US-11253525-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-02-22 | — | — | US | disclosed |
| US-20220048884-A1 | NRF2 ACTIVATOR | BIOGEN MA INC. | 2022-02-17 | — | — | US | disclosed |
| EP-3953335-A1 | INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS | Cellestia Biotech AG (CH) | 2022-02-16 | — | — | EP | disclosed |
| EP-3952997-A1 | COMPOUNDS FOR THE TREATMENT OF ONCOVIRUS INDUCED CANCER AND METHODS OF USE THEREOF | Cellestia Biotech AG (CH) | 2022-02-16 | — | — | EP | disclosed |
| WO-2021257851-A1 | THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. (US) | 2021-12-23 | — | — | WO | disclosed |
| EP-3915994-A1 | HYDROXYL-CONTAINING COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | Novartis AG (CH) | 2021-12-01 | — | — | EP | disclosed |
| EP-3555088-B1 | BISARYL AMIDES AS NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-11-24 | — | — | EP | disclosed |
| US-20210355113-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY | 2021-11-18 | — | — | US | disclosed |
| US-11174266-B2 | Efficient process for the preparation of sitagliptin | F.I.S.—Fabbrica Italiana Sintetici S.p.A. (IT) | 2021-11-16 | — | — | US | disclosed |
| US-20210347784-A1 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | NOVARTIS AG (CH) | 2021-11-11 | — | — | US | disclosed |
| EP-3906272-A1 | BRANCHED ORGANOSILICON COMPOUND, METHOD OF PREPARING SAME, AND COPOLYMER FORMED THEREWITH | Dow Silicones Corporation (US) | 2021-11-10 | — | — | EP | disclosed |
| EP-3297438-B1 | CCR2 MODULATORS | CHEMOCENTRYX INC (US) | 2021-10-20 | — | — | EP | disclosed |
| EP-3891154-A1 | 5-HYDROXY-7-OXABICYCLO[2.2.1]HEPTANE-2-CARBOXAMIDE DERIVATIVES FOR INDUCING CHONDROGENESIS FOR TREATING JOINT DAMAGE | Novartis AG (CH) | 2021-10-13 | — | — | EP | disclosed |
| EP-3890738-A1 | MACROCYCLIC COMPOUND AND USE THEREOF | Scohia Pharma, Inc. (JP) | 2021-10-13 | — | — | EP | disclosed |
| US-20210284638-A1 | ALPHAvBETA1 INTEGRIN ANTAGONISTS | SAINT LOUIS UNIVERSITY (US) | 2021-09-16 | — | — | US | disclosed |
| EP-3590947-B1 | METHOD FOR PRODUCING TRANSITION METAL-ISOCYANIDE COMPLEX | UNIV KYUSHU NAT UNIV CORP (JP) | 2021-08-18 | — | — | EP | disclosed |
| US-11091499-B2 | Compounds and compositions for inducing chondrogenesis | NOVARTIS AG (CH) | 2021-08-17 | — | — | US | disclosed |
| US-20210246136-A1 | CYCLOBUTANES- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-08-12 | — | — | US | disclosed |
| US-11078216-B2 | Bisaryl amides as NRF2 activators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-08-03 | — | — | US | disclosed |
| EP-3538519-B1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-07-28 | — | — | EP | disclosed |
| EP-3848378-A1 | TETRADENTATE DIAMINODIPHOSPHINE LIGAND AND TRANSITION METAL COMPLEX, AND METHOD FOR MANUFACTURING SAME AND APPLICATION FOR SAME | Takasago International Corporation (JP) | 2021-07-14 | — | — | EP | disclosed |
| US-11059784-B2 | Oxime ether compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-13 | — | — | US | disclosed |
| US-20210206758-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-07-08 | — | — | US | disclosed |
| US-20210188847-A1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-24 | — | — | US | disclosed |
| EP-3833662-A2 | INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | Janssen Pharmaceutica N.V. (BE) | 2021-06-16 | — | — | EP | disclosed |
| US-11034712-B2 | Method for producing transition metal-isocyanide complex | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2021-06-15 | — | — | US | disclosed |
| US-11028075-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-11028071-B2 | Indazole derivatives as alpha v integrin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-06-08 | — | — | US | disclosed |
| US-11014922-B2 | Cyclobutane- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-25 | — | — | US | disclosed |
| WO-2021096968-A1 | RADIOHALOGEN PROSTHETIC MOIETIES AND RADIOLABELED BIOMOLECULES | DUKE UNIVERSITY (US) | 2021-05-20 | — | — | WO | disclosed |
| US-20210147361-A1 | OXIME ETHER COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-05-20 | — | — | US | disclosed |
| EP-3119394-B1 | COMPOSITIONS AND METHODS COMPRISING 2-(ACYLAMINO)IMIDAZOLES | CURZA GLOBAL LLC (US) | 2021-05-12 | — | — | EP | disclosed |
| WO-2021070090-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS AG (CH) | 2021-04-15 | — | — | WO | disclosed |
| US-20210107889-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2021-04-15 | — | — | US | disclosed |
| EP-3475252-B1 | CATALYSTS AND PROCESSES FOR PRODUCING ALDEHYDES | EASTMAN CHEM CO (US) | 2021-04-14 | — | — | EP | disclosed |
| US-10968219-B2 | 3-substituted propionic acids as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-04-06 | — | — | US | disclosed |
| US-10959986-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-30 | — | — | US | disclosed |
| US-20210079010-A1 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | NOVARTIS AG (CH) | 2021-03-18 | — | — | US | disclosed |
| US-10947252-B2 | Inhibitors of KEAP1-Nrf2 protein-protein interaction | JANSSEN PHARMACEUTICA NV (BE) | 2021-03-16 | — | — | US | disclosed |
| US-20210061808-A1 | NEW EFFICIENT PROCESS FOR THE PREPARATION OF SITAGLIPTIN | F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2021-03-04 | — | — | US | disclosed |
| EP-3782996-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2021-02-24 | — | — | EP | disclosed |
| EP-3438113-B1 | TETRADENTATE LIGAND, AND PRODUCTION METHOD THEREFOR, SYNTHETIC INTERMEDIATE THEREOF, AND TRANSITION METAL COMPLEX THEREOF | TAKASAGO PERFUMERY CO LTD (JP) | 2021-02-17 | — | — | EP | disclosed |
| WO-2021021761-A1 | UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION | NURIX THERAPEUTICS, INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| EP-3766878-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2021-01-20 | — | — | EP | disclosed |
| EP-3759098-A1 | PYRIDINE-SULFONAMIDE COMPOUNDS AND THEIR USE AGAINST PAIN AND RELATED CONDITIONS | Genentech, Inc. (US) | 2021-01-06 | — | — | EP | disclosed |
| EP-3750896-A1 | CHIRAL TETRADENTATE LIGAND, METHOD FOR PRODUCING SAME AND TRANSITION METAL COMPLEX OF SAID CHIRAL TETRADENTATE LIGAND | Takasago International Corporation (JP) | 2020-12-16 | — | — | EP | disclosed |
| US-20200369700-A1 | CHIRAL TETRADENTATE LIGAND, METHOD FOR PRODUCING SAME AND TRANSITION METAL COMPLEX OF SAID CHIRAL TETRADENTATE LIGAND | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2020-11-26 | — | — | US | disclosed |
| US-20200339540-A1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-10-29 | — | — | US | disclosed |
| EP-3728174-A1 | SYNTHESIS OF ALKYL 2-ACETYL-5,9,13-TRIMETHYLTETRADECA-4,8,12-TRIENOATES AND DERIVATIVES BY A NON-CONTINUOUS PRODUCTION PROCESS | DSM IP Assets B.V. (NL) | 2020-10-28 | — | — | EP | disclosed |
| WO-2020208138-A1 | COMPOUNDS FOR THE TREATMENT OF ONCOVIRUS INDUCED CANCER AND METHODS OF USE THEREOF | CELLESTIA BIOTECH AG (CH) | 2020-10-15 | — | — | WO | disclosed |
| WO-2020208139-A1 | INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS | CELLESTIA BIOTECH AG (CH) | 2020-10-15 | — | — | WO | disclosed |
| EP-3307739-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-10-07 | — | — | EP | disclosed |
| US-20200308090-A1 | SYNTHESIS OF ALKYL 2-ACETYL-5,9,13-TRIMETHYLTETRADECA-4,8,12-TRIENOATES AND DERIVATIVES BY A NON-CONTINUOUS PRODUCTION PROCESS | DSM IP ASSETS B.V. (NL) | 2020-10-01 | — | — | US | disclosed |
| WO-2020185340-A1 | LOW-TEMPERATURE FORMATION OF GROUP 13-15 CERAMICS AND GROUP 13-15-16 CERAMICS | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2020-09-17 | — | — | WO | disclosed |
| US-20200291017-A1 | CITRATE SALT OF THE COMPOUND (S)-4-((S)-3-FLUORO-3-(2-(5,6,7,8-TETRAHYDRO-1,8-NAPHTHYDRIN-2-YL)ETHYL)PYRROLIDIN-1-YL)-3-(3-(2-METHOXYETHOXY)PHENYL) BUTANOIC ACID | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-09-17 | — | — | US | disclosed |
| EP-3307729-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-09-02 | — | — | EP | disclosed |
| US-10745384-B2 | Indazole derivatives as αv integrin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-18 | — | — | US | disclosed |
| US-10745550-B2 | Epoxy resin composition | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2020-08-18 | — | — | US | disclosed |
| US-20200237737-A1 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2020-07-30 | — | — | US | disclosed |
| WO-2020142370-A1 | BRANCHED ORGANOSILICON COMPOUND, METHOD OF PREPARING SAME, AND COPOLYMER FORMED THEREWITH | DOW SILICONES CORPORATION (US) | 2020-07-09 | — | — | WO | disclosed |
| EP-3433254-B1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-06-17 | — | — | EP | disclosed |
| WO-2020116660-A1 | MACROCYCLIC COMPOUND AND USE THEREOF | SCOHIA PHARMA, INC. (JP) | 2020-06-11 | — | — | WO | disclosed |
| WO-2020115683-A1 | 5-HYDROXY-7-OXABICYCLO[2.2.1]HEPTANE-2-CARBOXAMIDE DERIVATIVES FOR INDUCING CHONDROGENESIS FOR TREATING JOINT DAMAGE | NOVARTIS AG (CH) | 2020-06-11 | — | — | WO | disclosed |
| EP-3197894-B1 | NAPHTHYRIDINE DERIVATIVES AS ALPHA V BETA 6 INTEGRIN ANTAGONISTS FOR THE TREATMENT OF E.G. FIBROTIC DISEASES | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-06-03 | — | — | EP | disclosed |
| US-10660881-B2 | Compounds and compositions for inducing chondrogenesis | NOVARTIS AG (CH) | 2020-05-26 | — | — | US | disclosed |
| US-10662170-B2 | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-26 | — | — | US | disclosed |
| US-20200121688-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2020-04-23 | — | — | US | disclosed |
| EP-3634967-A1 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | Novartis AG (CH) | 2020-04-15 | — | — | EP | disclosed |
| US-10604509-B2 | Nrf2 regulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-31 | — | — | US | disclosed |
| US-20200079759-A1 | Nrf2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2020-03-12 | — | — | US | disclosed |
| EP-3197895-B1 | NAPHTHYRIDINE DERIVATIVES AS ALPHA V BETA 6 INTEGRIN ANTAGONISTS FOR THE TREATMENT OF FIBROTIC DISEASES | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-03-11 | — | — | EP | disclosed |
| US-20200069646-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL MYERS SQUIBB CO (US) | 2020-03-05 | — | — | US | disclosed |
| US-20200069695-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL MYERS SQUIBB CO (US) | 2020-03-05 | — | — | US | disclosed |
| US-20200071347-A1 | METHOD FOR PRODUCING TRANSITION METAL-ISOCYANIDE COMPLEX | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2020-03-05 | — | — | US | disclosed |
| WO-2020041169-A2 | INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-27 | — | — | WO | disclosed |
| US-20200055874-A1 | INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-20 | — | — | US | disclosed |
| US-10550141-B2 | Tetradentate ligand, and production method therefor, synthetic intermediate thereof, and transition metal complex thereof | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2020-02-04 | — | — | US | disclosed |
| WO-2020023356-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-01-30 | — | — | WO | disclosed |
| US-10513517-B2 | Naphthyridine derivatives as alpha V beta 6 integrin antagonists for the treatment of E.G. fibrotic diseases | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-12-24 | — | — | US | disclosed |
| US-10493061-B2 | Compositions and methods comprising 2-(acylamino)imidazoles | CURZA GLOBAL, LLC (US) | 2019-12-03 | — | — | US | disclosed |
| US-20190344254-A1 | CYCLIC SUPPORTED CATALYSTS | Universite Paris-Saclay (FR) | 2019-11-14 | — | — | US | disclosed |
| US-10463391-B2 | Magnetic ferrocenyl-functionalized nanoparticle | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2019-11-05 | — | — | US | disclosed |
| US-10464934-B2 | Substituted tetrahydropyrans as CCR2 modulators | CHEMOCENTRYX, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190330238-A1 | BISARYL AMIDES AS NRF2 ACTIVATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2019-10-31 | — | — | US | disclosed |
| EP-3555088-A1 | BISARYL AMIDES AS NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-10-23 | — | — | EP | disclosed |
| EP-3191453-B1 | PHENYL-(AZA)CYCLOALKYL CARBOXYLIC ACID GPR120 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-23 | — | — | EP | disclosed |
| US-10450312-B2 | Naphthyridine derivatives useful as alpha-V-beta-6 integrin antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-10-22 | — | — | US | disclosed |
| US-20190314348-A1 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2019-10-17 | — | — | US | disclosed |
| EP-3538526-A1 | CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | Bristol-Myers Squibb Company (US) | 2019-09-18 | — | — | EP | disclosed |
| EP-3538519-A1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2019-09-18 | — | — | EP | disclosed |
| EP-3538525-A1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | Bristol-Myers Squibb Company (US) | 2019-09-18 | — | — | EP | disclosed |
| US-20190275016-A1 | NOVEL COMPOUNDS avB6 INTEGRIN ANTAGONISTS. | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-09-12 | — | — | US | disclosed |
| US-20190270741-A1 | CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-05 | — | — | US | disclosed |
| EP-3532197-A1 | CYCLIC SUPPORTED CATALYSTS | Université Paris-Sud (FR) | 2019-09-04 | — | — | EP | disclosed |
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-10399933-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| WO-2019165290-A1 | PYRIDINE-SULFONAMIDE COMPOUNDS AND THEIR USE AGAINST PAIN AND RELATED CONDITIONS | GENENTECH, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
| US-20190263786-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-29 | — | — | US | disclosed |
| US-20190263808-A1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-08-29 | — | — | US | disclosed |
| US-20190256496-A1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-22 | — | — | US | disclosed |
| WO-2019158285-A1 | NEW EFFICIENT PROCESS FOR THE PREPARATION OF SITAGLIPTIN. | F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2019-08-22 | — | — | WO | disclosed |
| US-10383863-B2 | Compounds and compositions for inducing chondrogenesis | NOVARTIS AG (CH) | 2019-08-20 | — | — | US | disclosed |
| US-10370397-B2 | Phosphine substituted ferrocenyl complex | Kind Fahd University of Petroleum and Minerals (SA) | 2019-08-06 | — | — | US | disclosed |
| US-20190224212-A1 | Nrf2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2019-07-25 | — | — | US | disclosed |
| US-10342783-B2 | Compounds αvβ6 integrin antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-09 | — | — | US | disclosed |
| US-10336684-B2 | Phenyl-(aza)cycloalkyl carboxylic acid GPR120 modulators | BRISTOL=MYERS SQUIBB COMPANY (US) | 2019-07-02 | — | — | US | disclosed |
| US-20190134012-A1 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION (GNF) | 2019-05-09 | — | — | US | disclosed |
| US-20190127407-A1 | TETRADENTATE LIGAND, AND PRODUCTION METHOD THEREFOR, SYNTHETIC INTERMEDIATE THEREOF, AND TRANSITION METAL COMPLEX THEREOF | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2019-05-02 | — | — | US | disclosed |
| US-20190127572-A1 | EPOXY RESIN COMPOSITION | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2019-05-02 | — | — | US | disclosed |
| EP-3475252-A1 | CATALYSTS AND PROCESSES FOR PRODUCING ALDEHYDES | Eastman Chemical Company (US) | 2019-05-01 | — | — | EP | disclosed |
| US-10272095-B2 | NRF2 regulators | GlaxoSmithKline Intellectual Propert Development Limited (GB) | 2019-04-30 | — | — | US | disclosed |
| US-10266532-B2 | Tricyclic modulators of TNF signaling | ABBVIE INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20190112306-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-04-18 | — | — | US | disclosed |
| US-10253038-B2 | Fusicoccane derivatives and methods | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-10227355-B2 | Quinoline derivatives and preparation thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2019-03-12 | — | — | US | disclosed |
| EP-3166918-B1 | METAL-CATALYZED ASYMMETRIC 1,4-CONJUGATE ADDITION OF VINYLBORON COMPOUNDS TO 2-SUBSTITUTED-4-OXY- CYCLOPENT-2-EN-1-ONES YIELDING PROSTAGLANDINS AND PROSTAGLANDIN ANALOGS | SCINOPHARM TAIWAN LTD (TW) | 2019-02-20 | — | — | EP | disclosed |
| WO-2019032631-A1 | OXIME ETHER COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-02-14 | — | — | WO | disclosed |
| US-20190048005-A1 | NAPHTHYRIDINE DERIVATIVES AS ALPHA V BETA 6 INTEGRIN ANTAGONISTS FOR THE TREATMENT OF E.G. FIBROTIC DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-02-14 | — | — | US | disclosed |
| EP-3438113-A1 | TETRADENTATE LIGAND, AND PRODUCTION METHOD THEREFOR, SYNTHETIC INTERMEDIATE THEREOF, AND TRANSITION METAL COMPLEX THEREOF | Takasago International Corporation (JP) | 2019-02-06 | — | — | EP | disclosed |
| US-10195178-B2 | GPR40 agonists in anti-diabetic drug combinations | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-05 | — | — | US | disclosed |
| US-20190029718-A1 | MAGNETIC FERROCENYL-FUNCTIONALIZED NANOPARTICLE | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2019-01-31 | — | — | US | disclosed |
| US-20190031697-A1 | PHOSPHINE SUBSTITUTED FERROCENYL COMPLEX | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2019-01-31 | — | — | US | disclosed |
| EP-3433254-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-01-30 | — | — | EP | disclosed |
| EP-3433255-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-01-30 | — | — | EP | disclosed |
| US-10188638-B2 | Compounds and compositions for inducing chondrogenesis | NOVARTIS AG (CH) | 2019-01-29 | — | — | US | disclosed |
| EP-3430003-A1 | CITRATE SALT OF THE COMPOUND (S)-4-((S)-3-FLUORO-3-(2-(5,6,7,8-TETRAHYDRO-1,8-NAPHTHYDRIN-2-YL)ETHYL)PYRROLIDIN-1-YL)-3-(3-(2-METHOXYETHOXY)PHENYL) BUTANOIC ACID | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-01-23 | — | — | EP | disclosed |
| US-20190016707-A1 | COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS | GENZYME CORPORATION | 2019-01-17 | — | — | US | disclosed |
| EP-3428167-A1 | NAPHTHYRIDINE DERIVATIVES AS ALPHA V BETA 6 INTEGRIN ANTAGONISTS FOR THE TREATMENT OF FIBROTIC DISEASES | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-01-16 | — | — | EP | disclosed |
| US-10172814-B2 | Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-01-08 | — | — | US | disclosed |
| US-10167254-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-01 | — | — | US | disclosed |
| US-10160748-B2 | Indazolones as modulators of tnf signaling | ABBVIE INC. (US) | 2018-12-25 | — | — | US | disclosed |
| WO-2018225009-A1 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | NOVARTIS AG (CH) | 2018-12-13 | — | — | WO | disclosed |
| US-10144733-B2 | Naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of E.G. fibrotic diseases | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-12-04 | — | — | US | disclosed |
| US-10131648-B2 | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-20 | — | — | US | disclosed |
| US-10125159-B2 | Functionalized magnetic nanoparticle, a catalyst, a method for forming C—C bonds | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2018-11-13 | — | — | US | disclosed |
| US-20180319737-A1 | PHENYL-(AZA)CYCLOALKYL CARBOXYLIC ACID GPR120 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-11-08 | — | — | US | disclosed |
| US-20180312518-A1 | Fusicoccane Derivatives and Methods | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2018-11-01 | — | — | US | disclosed |
| US-20180291022-A1 | NAPHTHYRIDINE DERIVATIVES USEFUL AS ALPHA-V-BETA-6 INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-10-11 | — | — | US | disclosed |
| US-10093606-B2 | Method of producing farnesyl acetone | BASF SE (REITSTÖTTER, KINZEBACH & PARTNER) (DE) | 2018-10-09 | — | — | US | disclosed |
| US-10087179-B2 | Fused tricyclic imidazole derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2018-10-02 | — | — | US | disclosed |
| US-20180271845-A1 | NOVEL COMPOUNDS ALPHA v BETA 6 INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-09-27 | — | — | US | disclosed |
| EP-3197892-B1 | NAPHTHYRIDINE DERIVATIVES AS ALPHA V BETA 6 INTEGRIN ANTAGONISTS FOR THE TREATMENT OF E.G. FIBROTIC DISEASES | GLAXOSMITHKLINE IP DEV LTD (GB) | 2018-09-05 | — | — | EP | disclosed |
| US-20180242582-A1 | MACROCYCLIC PICOLINAMIDES AS FUNGICIDES | DOW AGROSCIENCES LLC (US) | 2018-08-30 | — | — | US | disclosed |
| US-20180237448-A1 | NOVEL QUINOLINE DERIVATIVES AND PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2018-08-23 | — | — | US | disclosed |
| WO-2018140876-A1 | NRF2 ACTIVATOR | BIOGEN MA INC. (US) | 2018-08-02 | — | — | WO | disclosed |
| EP-2855413-B1 | CATALYSTS AND PROCESSES FOR PREPARING ALDEHYDES | EASTMAN CHEM CO (US) | 2018-07-25 | — | — | EP | disclosed |
| US-10023568-B2 | Naphthyridine derivatives useful as αvβ6 integrin antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-07-17 | — | — | US | disclosed |
| US-20180179198-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180179167-A1 | Nrf2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2018-06-28 | — | — | US | disclosed |
| US-20180179187-A1 | Nrf2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2018-06-28 | — | — | US | disclosed |
| US-10004724-B2 | Compounds alpha v beta 6 integrin antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-26 | — | — | US | disclosed |
| US-10004701-B2 | Methods and compositions for treating infection | UNIVERSITY OF ROCHESTER (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180169110-A1 | Nrf2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2018-06-21 | — | — | US | disclosed |
| WO-2018109647-A1 | BISARYL AMIDES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018104766-A1 | 3-(2,3-DIHYDRO-1H-INDEN-5-YL)PROPANOIC ACID DERIVATIVES AND THEIR USE AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-14 | — | — | WO | disclosed |
| EP-3325471-A1 | COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS | Genzyme Corporation (US) | 2018-05-30 | — | — | EP | disclosed |
| WO-2018089353-A1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018089357-A1 | INDAZOLE DERIVATIVES AS αV INTEGRIN ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018089355-A1 | CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
| US-9955691-B2 | Macrocyclic picolinamides as fungicides | DOW AGROSCIENCES LLC (US) | 2018-05-01 | — | — | US | disclosed |
| US-9956209-B2 | Compounds αv β6 integrin antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-05-01 | — | — | US | disclosed |
| EP-3307719-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-04-18 | — | — | EP | disclosed |
| EP-3307729-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-04-18 | — | — | EP | disclosed |
| EP-2855412-B1 | CATALYSTS AND PROCESS FOR PRODUCING ALDEHYDES | EASTMAN CHEM CO (US) | 2018-04-18 | — | — | EP | disclosed |
| US-20180099987-A1 | FUNCTIONALIZED MAGNETIC NANOPARTICLE, A CATALYST, A METHOD FOR FORMING C-C BONDS | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2018-04-12 | — | — | US | disclosed |
| US-20180086737-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-03-29 | — | — | US | disclosed |
| US-20180086756-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2018-03-29 | — | — | US | disclosed |
| EP-3297438-A1 | CCR2 MODULATORS | ChemoCentryx, Inc. (US) | 2018-03-28 | — | — | EP | disclosed |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-22 | — | — | US | disclosed |
| US-20180072660-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-15 | — | — | US | disclosed |
| EP-3288939-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | AbbVie Inc. (US) | 2018-03-07 | — | — | EP | disclosed |
| EP-2989100-B1 | NAPHTHYRIDINE DERIVATIVES USEFUL AS ALPHA-V-BETA-6 INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2018-02-28 | — | — | EP | disclosed |
| EP-3027606-B1 | COMPOUNDS FOR ENHANCING THE COGNITIVE FUNCTION | UCB BIOPHARMA SPRL (BE) | 2018-02-28 | — | — | EP | disclosed |
| EP-3277670-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | Bristol-Myers Squibb Company (US) | 2018-02-07 | — | — | EP | disclosed |
| EP-3277671-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | Bristol-Myers Squibb Company (US) | 2018-02-07 | — | — | EP | disclosed |
| EP-3277672-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | Bristol-Myers Squibb Company (US) | 2018-02-07 | — | — | EP | disclosed |
| US-9856253-B2 | Tricyclic modulators of TNF signaling | ABBVIE, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| WO-2017223271-A1 | CATALYSTS AND PROCESSES FOR PRODUCING ALDEHYDES | EASTMAN CHEMICAL COMPANY (US) | 2017-12-28 | — | — | WO | disclosed |
| US-20170362196-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-12-21 | — | — | US | disclosed |
| US-20170354620-A1 | SUBSTITUTED PYRIDYL-CYCLOALKYL-CARBOXYLIC ACIDS, COMPOSITIONS CONTAINING THEM AND MEDICAL USES THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-12-14 | — | — | US | disclosed |
| US-20170327457-A1 | PHENYL-(AZA)CYCLOALKYL CARBOXYLIC ACID GPR120 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-16 | — | — | US | disclosed |
| EP-3233802-A1 | SUBSTITUTED PYRIDYL-CYCLOALKYL-CARBOXYLIC ACIDS, COMPOSITIONS CONTAINING THEM AND MEDICAL USES THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2017-10-25 | — | — | EP | disclosed |
| US-9796678-B2 | Method for manufacturing optically active compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-10-24 | — | — | US | disclosed |
| WO-2017180457-A1 | GPR40 AGONISTS IN ANTI-DIABETIC DRUG COMBINATIONS | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-19 | — | — | WO | disclosed |
| US-9790198-B2 | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-17 | — | — | US | disclosed |
| US-9790169-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170290800-A1 | GPR40 AGONISTS IN ANTI-DIABETIC DRUG COMBINATIONS | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-12 | — | — | US | disclosed |
| US-20170291899-A1 | NAPHTHYRIDINE DERIVATIVES AS ALPHA V BETA 6 INTEGRIN ANTAGONISTS FOR THE TREATMENT OF E.G. FIBROTIC DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-12 | — | — | US | disclosed |
| US-20170290818-A1 | NOVEL COMPOUNDS ALPHA v BETA 6 INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-12 | — | — | US | disclosed |
| US-20170290817-A1 | NOVEL COMPOUNDS ALPHA v BETA 6 INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-12 | — | — | US | disclosed |
| US-9783540-B2 | Substituted tetrahydropyrans as CCR2 modulators | CHEMOCENTRYX, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| WO-2017162570-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017162572-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017158072-A1 | CITRATE SALT OF THE COMPOUND (S)-4-((S)-3-FLUORO-3-(2-(5,6,7,8-TETRAHYDRO-1,8-NAPHTHYDRIN-2-YL)ETHYL)PYRROLIDIN-1-YL)-3-(3-(2-METHOXYETHOXY)PHENYL) BUTANOIC ACID | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-09-21 | — | — | WO | disclosed |
| US-9758499-B2 | Stereo controlled synthesis of (E,Z)-dienals via tandem Rh(I) catalyzed propargyl claisen rearrangement | The Florida State University Research Foundation, Inc. (US) | 2017-09-12 | — | — | US | disclosed |
| EP-2872514-B1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-30 | — | — | EP | disclosed |
| US-9744252-B2 | Compounds for binding to the platelet specific glycoprotein IIb/IIIa and their use for imaging of thrombi | PIRAMAL IMAGING SA (CH) | 2017-08-29 | — | — | US | disclosed |
| US-20170239227-A1 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2017-08-24 | — | — | US | disclosed |
| US-20170231999-A1 | IDO INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-17 | — | — | US | disclosed |
| EP-3204361-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | Janssen Pharmaceutica N.V. (BE) | 2017-08-16 | — | — | EP | disclosed |
| EP-3197892-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2017-08-02 | — | — | EP | disclosed |
| EP-3197895-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2017-08-02 | — | — | EP | disclosed |
| EP-3197894-A1 | NAPHTHYRIDINE DERIVATIVES AS ALPHA V BETA 6 INTEGRIN ANTAGONISTS FOR THE TREATMENT OF E.G. FIBROTIC DISEASES | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2017-08-02 | — | — | EP | disclosed |
| US-9718774-B2 | Indole carboxamide derivatives as P2X7 receptor antagonist | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-08-01 | — | — | US | disclosed |
| EP-3191453-A1 | PHENYL-(AZA)CYCLOALKYL CARBOXYLIC ACID GPR120 MODULATORS | Bristol-Myers Squibb Company (US) | 2017-07-19 | — | — | EP | disclosed |
| EP-2937355-B1 | PHOSPHORUS COMPOUND AND TRANSITION METAL COMPLEX OF THE SAME | TAKASAGO PERFUMERY CO LTD (JP) | 2017-06-28 | — | — | EP | disclosed |
| US-9688689-B2 | Compounds and compositions for inducing chondrogenesis | NOVARTIS AG (CH) | 2017-06-27 | — | — | US | disclosed |
| US-9670234-B2 | Metal-catalyzed asymmetric 1,4-conjugate addition of vinylboron compounds to 2-substituted-4-oxy-cyclopent-2-en-1-ones yielding prostaglandins and prostaglandin analogs | SCINOPHARM TAIWAN, LTD. (TW) | 2017-06-06 | — | — | US | disclosed |
| EP-3166918-A1 | METAL-CATALYZED ASYMMETRIC 1,4-CONJUGATE ADDITION OF VINYLBORON COMPOUNDS TO 2-SUBSTITUTED-4-OXY- CYCLOPENT-2-EN-1-ONES YIELDING PROSTAGLANDINS AND PROSTAGLANDIN ANALOGS | Scinopharm Taiwan, Ltd. (TW) | 2017-05-17 | — | — | EP | disclosed |
| EP-3166936-A1 | MACROCYCLIC PICOLINAMIDES AS FUNGICIDES | Dow AgroSciences LLC (US) | 2017-05-17 | — | — | EP | disclosed |
| US-9649625-B1 | Catalysts and processes for producing aldehydes | EASTMAN CHEMICAL COMPANY (US) | 2017-05-16 | — | — | US | disclosed |
| US-20170129865-A1 | STEREO CONTROLLED SYNTHESIS OF (E,Z)-DIENALS VIA TANDEM RH(I) CATALYZED PROPARGYL CLAISEN REARRANGEMENT | The Florida State University Research Foundation, Inc. | 2017-05-11 | — | — | US | disclosed |
| US-9643168-B2 | Metal entrapped compounds | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) | 2017-05-09 | — | — | US | disclosed |
| EP-3157330-A1 | COMPOSITIONS AND METHODS FOR ATTRACTING STINK BUGS | Bedoukian Research, Inc. (US) | 2017-04-26 | — | — | EP | disclosed |
| US-9630948-B2 | Compounds for enhancing the cognitive function | UCB PHARMA, S.A. (BE) | 2017-04-25 | — | — | US | disclosed |
| US-20170100375-A1 | COMPOSITIONS AND METHODS COMPRISING 2-(ACYLAMINO)IMIDAZOLES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-04-13 | — | — | US | disclosed |
| EP-2855414-B1 | CATALYST AND METHOD HAVING IMPROVED SELECTIVITY TO ISOBUTYRALDEHYDE VIA CATLAYST INDUCTION | EASTMAN CHEM CO (US) | 2017-03-29 | — | — | EP | disclosed |
| EP-3143026-A1 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | Novartis AG (CH) | 2017-03-22 | — | — | EP | disclosed |
| US-20170065540-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | UNIVERSITY OF ROCHESTER (US) | 2017-03-09 | — | — | US | disclosed |
| EP-3137445-A1 | METHOD OF PRODUCING FARNESYLACETONE | BASF SE (DE) | 2017-03-08 | — | — | EP | disclosed |
| US-9586192-B2 | Functionalized media and methods of making and using therefor | BROWN UNIVERSITY (US) | 2017-03-07 | — | — | US | disclosed |
| US-9573871-B2 | Stereo controlled synthesis of (E,Z)-dienals via tandem Rh(I) catalyzed propargyl claisen rearrangement | The Florida State University Research Foundation, Inc. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20170044084-A1 | METHOD OF PRODUCING FARNESYL ACETONE | BASF SE (DE) | 2017-02-16 | — | — | US | disclosed |
| US-20170029453-A1 | BIS(PHOSPHINE)-CARBODICARBENE CATALYST COMPLEXES AND METHODS OF USING THE SAME | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-02-02 | — | — | US | disclosed |
| US-9556117-B2 | Indole carboxamide derivatives as P2X7 receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2017-01-31 | — | — | US | disclosed |
| US-20170022162-A1 | METHOD FOR MANUFACTURING OPTICALLY ACTIVE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-01-26 | — | — | US | disclosed |
| WO-2017015267-A1 | COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS | GENZYME CORPORATION (US) | 2017-01-26 | — | — | WO | disclosed |
| EP-3119394-A2 | COMPOSITIONS AND METHODS COMPRISING 2-(ACYLAMINO)IMIDAZOLES | Curza Global LLC (US) | 2017-01-25 | — | — | EP | disclosed |
| US-20170008876-A1 | Metal Chelate Compounds for Binding to the Platelet Specific Glycoprotein IIb/IIIa | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-12 | — | — | US | disclosed |
| EP-2744802-B1 | COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIB/IIIA AND THEIR USE FOR IMAGING OF THROMBI | PIRAMAL IMAGING SA (CH) | 2017-01-04 | — | — | EP | disclosed |
| US-20160376268-A1 | Fused Tricyclic Imidazole Derivatives As Modulators of TNF Activity | SANOFI (FR) | 2016-12-29 | — | — | US | disclosed |
| WO-2016203401-A1 | NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-12-22 | — | — | WO | disclosed |
| WO-2016203400-A1 | NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-12-22 | — | — | WO | disclosed |
| EP-3105221-A1 | METAL CHELATE COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIB/IIIA | Bayer Pharma Aktiengesellschaft (DE) | 2016-12-21 | — | — | EP | disclosed |
| EP-2931717-B1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-12-07 | — | — | EP | disclosed |
| US-9505753-B2 | Inhibitors of D-amino acid oxidase | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-11-29 | — | — | US | disclosed |
| WO-2016187393-A1 | CCR2 MODULATORS | CHEMOCENTRYX, INC. (US) | 2016-11-24 | — | — | WO | disclosed |
| US-20160340356-A1 | CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2016-11-24 | — | — | US | disclosed |
| EP-2935211-B1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-11-09 | — | — | EP | disclosed |
| WO-2016168641-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. (US) | 2016-10-20 | — | — | WO | disclosed |
| US-20160304496-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160304517-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | disclosed |
| WO-2016161279-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016161269-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016161286-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-06 | — | — | WO | disclosed |
| US-20160289171-A1 | IDO INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-06 | — | — | US | disclosed |
| US-20160280705-A1 | NAPHTHYRIDINE DERIVATIVES USEFUL AS ALPHA-V-BETA-6 INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-09-29 | — | — | US | disclosed |
| US-9416148-B2 | Phosphorus compound and transition metal complex of the same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2016-08-16 | — | — | US | disclosed |
| WO-2016125187-A1 | NOVEL QUINOLINE DERIVATIVES AND PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-08-11 | — | — | WO | disclosed |
| US-20160185761-A1 | Compounds for Enhancing the Cognitive Function | UCB PHARMA, S.A. (BE) | 2016-06-30 | — | — | US | disclosed |
| WO-2016097013-A1 | SUBSTITUTED PYRIDYL-CYCLOALKYL-CARBOXYLIC ACIDS, COMPOSITIONS CONTAINING THEM AND MEDICAL USES THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-23 | — | — | WO | disclosed |
| EP-3027606-A1 | COMPOUNDS FOR ENHANCING THE COGNITIVE FUNCTION | UCB Pharma, S.A. (BE) | 2016-06-08 | — | — | EP | disclosed |
| US-20160152550-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2,3-DIHYDROFARNESAL | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2016-06-02 | — | — | US | disclosed |
| US-9345793-B2 | Compounds for binding to the platelet specific glycoprotein IIB/IIIA and their use for imaging of thrombi | PIRAMAL IMAGING SA (CH) | 2016-05-24 | — | — | US | disclosed |
| US-20160137629-A1 | COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIb/IIIa AND THEIR USE FOR IMAGING OF THROMBI | PIRAMAL IMAGING SA (CH) | 2016-05-19 | — | — | US | disclosed |
| US-20160108050-A1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-21 | — | — | US | disclosed |
| WO-2016057731-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-14 | — | — | WO | disclosed |
| US-20160102071-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-14 | — | — | US | disclosed |
| WO-2016046230-A1 | NAPHTHYRIDINE DERIVATIVES AS ALPHA V BETA 6 INTEGRIN ANTAGONISTS FOR THE TREATMENT OF E.G. FIBROTIC DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016046241-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016046225-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016040225-A1 | PHENYL-(AZA)CYCLOALKYL CARBOXYLIC ACID GPR120 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-17 | — | — | WO | disclosed |
| US-9284246-B2 | Method for producing optically active 2,3-dihydrofarnesal | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2016-03-15 | — | — | US | disclosed |
| US-20160058006-A1 | COMPOSITIONS AND METHODS FOR ATTRACTING STINK BUGS | BEDOUKIAN RESEARCH, INC. | 2016-03-03 | — | — | US | disclosed |
| WO-2016033069-A1 | COMPOSITIONS AND METHODS FOR ATTRACTING STINK BUGS | BEDOUKIAN RESEARCH, INC. (US) | 2016-03-03 | — | — | WO | disclosed |
| EP-2989100-A1 | NAPHTHYRIDINE DERIVATIVES USEFUL AS ALPHA-V-BETA-6 INTEGRIN ANTAGONISTS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2016-03-02 | — | — | EP | disclosed |
| US-9273057-B2 | Imidazotriazinecarbonitriles useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-01 | — | — | US | disclosed |
| US-20160008490-A1 | METAL CHELATE COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIB/IIIA | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-01-14 | — | — | US | disclosed |
| US-20160007601-A1 | MACROCYCLIC PICOLINAMIDES AS FUNGICIDES | DOW AGROSCIENCES LLC | 2016-01-14 | — | — | US | disclosed |
| WO-2016005943-A1 | METAL-CATALYZED ASYMMETRIC 1,4-CONJUGATE ADDITION OF VINYLBORON COMPOUNDS TO 2-SUBSTITUTED-4-OXY- CYCLOPENT-2-EN-L-ONES YIELDING PROSTAGLANDINS AND PROSTAGLANDIN ANALOGS | SCINOPHARM TAIWAN, LTD. (TW) | 2016-01-14 | — | — | WO | disclosed |
| WO-2016007529-A1 | MACROCYCLIC PICOLINAMIDES AS FUNGICIDES | DOW AGROSCIENCES LLC (US) | 2016-01-14 | — | — | WO | disclosed |
| US-20160009740-A1 | METAL-CATALYZED ASYMMETRIC 1,4-CONJUGATE ADDITION OF VINYLBORON COMPOUNDS TO 2-SUBSTITUTED-4-OXY-CYCLOPENT-2-EN-1-ONES YIELDING PROSTAGLANDINS AND PROSTAGLANDIN ANALOGS | SCINOPHARM TAIWAN, LTD. (TW) | 2016-01-14 | — | — | US | disclosed |
| EP-2956461-A1 | METAL CHELATE COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIB/IIIA | Bayer Pharma Aktiengesellschaft (DE) | 2015-12-23 | — | — | EP | disclosed |
| US-20150361019-A1 | STERO CONTROLLED SYNTHESIS OF (E,Z)-DIENALS VIA TANDEM RH(I) CATALYZED PROPARGYL CLAISEN REARRANGEMENT | The Florida State University Research Foundation, Inc. | 2015-12-17 | — | — | US | disclosed |
| US-20150344425-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-12-03 | — | — | US | disclosed |
| US-20150329554-A1 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | NOVARTIS AG (CH) | 2015-11-19 | — | — | US | disclosed |
| WO-2015175487-A1 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | NOVARTIS AG (CH) | 2015-11-19 | — | — | WO | disclosed |
| US-20150322008-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONIST | ACTELION PHARMACEUTICALS LTD (CH) | 2015-11-12 | — | — | US | disclosed |
| US-20150313889-A1 | HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE | AJINOMOTO CO., INC. (JP) | 2015-11-05 | — | — | US | disclosed |
| WO-2015165959-A1 | METHOD OF PRODUCING FARNESYL ACETONE | BASF SE (DE) | 2015-11-05 | — | — | WO | disclosed |
| US-20150307531-A1 | PHOSPHORUS COMPOUND AND TRANSITION METAL COMPLEX OF THE SAME | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-10-29 | — | — | US | disclosed |
| US-20150306273-A1 | MEDICAL SEALANT COMPOSITION AND METHOD OF USING SAME | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2015-10-29 | — | — | US | disclosed |
| EP-2935211-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2015-10-28 | — | — | EP | disclosed |
| EP-2937355-A1 | PHOSPHORUS COMPOUND AND TRANSITION METAL COMPLEX OF THE SAME | Takasago International Corporation (JP) | 2015-10-28 | — | — | EP | disclosed |
| EP-2934610-A1 | MEDICAL SEALANT COMPOSITION AND METHOD OF USING SAME | 3M Innovative Properties Company (US) | 2015-10-28 | — | — | EP | disclosed |
| WO-2015159225-A1 | BIS(PHOSPHINE)-CARBODICARBENE CATALYST COMPLEXES AND METHODS OF USING THE SAME | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2015-10-22 | — | — | WO | disclosed |
| EP-2931717-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2015-10-21 | — | — | EP | disclosed |
| US-9150592-B2 | Heterocyclic nuclear hormone receptor modulators | ABBVIE INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20150274777-A1 | KETOAMIDE IMMUNOPROTEASOME INHIBITORS | HOFFMANN-LA ROCHE INC. | 2015-10-01 | — | — | US | disclosed |
| WO-2015143240-A2 | COMPOSITIONS AND METHODS COMPRISING 2-(ACYLAMINO)IMIDAZOLES | CURZA GLOBAL, LLC (US) | 2015-09-24 | — | — | WO | disclosed |
| US-9139714-B2 | Method for producing dialkylphosphinic acids and esters and salts thereof by means of allyl alcohols-acroleins and use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2015-09-22 | — | — | US | disclosed |
| US-20150238473-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-27 | — | — | US | disclosed |
| US-9115107-B2 | Heteroarylcarboxylic acid ester derivative | AJINOMOTO CO., INC. (JP) | 2015-08-25 | — | — | US | disclosed |
| WO-2015121163-A1 | METAL CHELATE COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIB/IIIA | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-20 | — | — | WO | disclosed |
| EP-2906581-A1 | KETOAMIDE IMMUNOPROTEASOME INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2015-08-19 | — | — | EP | disclosed |
| US-20150218156-A1 | INHIBITORS OF D-AMINO ACID OXIDASE | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-08-06 | — | — | US | disclosed |
| US-20150218072-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2,3-DIHYDROFARNESAL | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-08-06 | — | — | US | disclosed |
| US-20150210697-A1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-30 | — | — | US | disclosed |
| EP-2894143-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2,3-DIHYDROFARNESAL | Takasago International Corporation (JP) | 2015-07-15 | — | — | EP | disclosed |
| US-20150190780-A1 | FUNCTIONALIZED MEDIA AND METHODS OF MAKING AND USING THEREFOR | NATIONAL SCIENCE FOUNDATION | 2015-07-09 | — | — | US | disclosed |
| EP-2872514-A1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2015-05-20 | — | — | EP | disclosed |
| US-9012443-B2 | Bicyclic aryl and heteroaryl sodium channel inhibitors | AMGEN INC. (US) | 2015-04-21 | — | — | US | disclosed |
| EP-2855412-A1 | CATALYSTS AND PROCESS FOR PRODUCING ALDEHYDES | Eastman Chemical Company (US) | 2015-04-08 | — | — | EP | disclosed |
| EP-2855414-A1 | CATALYST AND METHOD HAVING IMPROVED SELECTIVITY TO ISOBUTYRALDEHYDE VIA CATLAYST INDUCTION | Eastman Chemical Company (US) | 2015-04-08 | — | — | EP | disclosed |
| EP-2855413-A1 | CATALYSTS AND PROCESSES FOR PREPARING ALDEHYDES | Eastman Chemical Company (US) | 2015-04-08 | — | — | EP | disclosed |
| US-20150072969-A1 | PHENYL ALKANOIC ACID DERIVATIVES AS GPR AGONISTS | Piramal Enterprises Limited (IN) | 2015-03-12 | — | — | US | disclosed |
| US-20150065738-A1 | PHOSPHOROUS COMPOUND AND TRANSITION METAL COMPLEX THEREOF | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-03-05 | — | — | US | disclosed |
| EP-2842959-A1 | Phosphorous compound and transition metal complex thereof | Takasago International Corporation (JP) | 2015-03-04 | — | — | EP | disclosed |
| WO-2015014785-A1 | COMPOUNDS FOR ENHANCING THE COGNITIVE FUNCTION | UCB PHARMA, S.A. (BE) | 2015-02-05 | — | — | WO | disclosed |
| EP-2511271-B1 | HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE | AJINOMOTO KK (JP) | 2015-01-21 | — | — | EP | disclosed |
| US-20150011511-A1 | HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE | AJINOMOTO CO., INC. (JP) | 2015-01-08 | — | — | US | disclosed |
| EP-2820005-A1 | PHENYL ALKANOIC ACID DERIVATIVES AS GPR AGONISTS | Piramal Enterprises Limited (IN) | 2015-01-07 | — | — | EP | disclosed |
| US-8921608-B2 | Catalyst and method having selectivity to isobutyraldehyde via catalyst induction | EASTMAN CHEMICAL COMPANY (US) | 2014-12-30 | — | — | US | disclosed |
| US-20140336196-A1 | PHOSPHORIC ACID SALTS OF SITAGLIPTIN | MERCK SHARP & DOHME CORP. (US) | 2014-11-13 | — | — | US | disclosed |
| US-8877805-B2 | Heteroarylcarboxylic acid ester derivative | AJINOMOTO CO., INC. (JP) | 2014-11-04 | — | — | US | disclosed |
| US-20140314669-A1 | COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIB/IIIA AND THEIR USE FOR IMAGING OF THROMBI | PIRAMAL IMAGING SA (CH) | 2014-10-23 | — | — | US | disclosed |
| WO-2014167017-A1 | METHOD FOR PRODUCING ORTHO-ACYLATED AROMATIC OR HETEROAROMATIC CARBOXYLIC ACIDS | SALTIGO GMBH (DE) | 2014-10-16 | — | — | WO | disclosed |
| EP-2789600-A1 | Method for the preparation of ortho-acylated aromatic or heteroaromatic carboxylic acids | Saltigo GmbH (DE) | 2014-10-15 | — | — | EP | disclosed |
| EP-2788332-A1 | BICYCLIC ARYL AND HETEROARYL SODIUM CHANNEL INHIBITORS | AMGEN, INC. (US) | 2014-10-15 | — | — | EP | disclosed |
| WO-2014154725-A1 | NAPHTHYRIDINE DERIVATIVES USEFUL AS ALPHA-V-BETA-6 INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014124943-A1 | METAL CHELATE COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIB/IIIA | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-08-21 | — | — | WO | disclosed |
| EP-2593426-B1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | HOFFMANN LA ROCHE (CH) | 2014-08-20 | — | — | EP | disclosed |
| US-8765730-B2 | 1-hydroxyimino-3-phenyl-propanes | Hoffmann-La Roche Inc (US) | 2014-07-01 | — | — | US | disclosed |
| WO-2014099637-A1 | MEDICAL SEALANT COMPOSITION AND METHOD OF USING SAME | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014097140-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-06-26 | — | — | WO | disclosed |
| US-20140179676-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | ABBVIE INC. (US) | 2014-06-26 | — | — | US | disclosed |
| EP-2744802-A1 | COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIB/IIIA AND THEIR USE FOR IMAGING OF THROMBI | Piramal Imaging SA (CH) | 2014-06-25 | — | — | EP | disclosed |
| WO-2014091415-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-06-19 | — | — | WO | disclosed |
| EP-2743268-A2 | Fused cyclic compounds as GPR40 receptor modulators | Takeda Pharmaceutical Company Limited (JP) | 2014-06-18 | — | — | EP | disclosed |
| US-8709377-B2 | Molecular hydrogen stores and hydrogen transfer reagents for hydrogenation reactions | UNIVERSITAT HEIDELBERG (DE) | 2014-04-29 | — | — | US | disclosed |
| WO-2014056748-A1 | KETOAMIDE IMMUNOPROTEASOME INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-04-17 | — | — | WO | disclosed |
| US-20140080891-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-20 | — | — | US | disclosed |
| US-20140080790-A1 | HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE | AJINOMOTO CO., INC. (JP) | 2014-03-20 | — | — | US | disclosed |
| WO-2014025993-A1 | INHIBITORS OF D-AMINO ACID OXIDASE | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-02-13 | — | — | WO | disclosed |
| WO-2014015264-A1 | FUNCTIONALIZED MEDIA AND METHODS OF MAKING AND USING THEREFOR | BROWN UNIVERSITY (US) | 2014-01-23 | — | — | WO | disclosed |
| WO-2014011974-A1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-16 | — | — | WO | disclosed |
| US-8609715-B2 | Heteroarylcarboxylic acid ester derivative | AJINOMOTO CO., INC. (JP) | 2013-12-17 | — | — | US | disclosed |
| WO-2013181190-A1 | CATALYSTS AND PROCESSES FOR PREPARING ALDEHYDES | EASTMAN CHEMICAL COMPANY (US) | 2013-12-05 | — | — | WO | disclosed |
| US-20130324767-A1 | CATALYSTS AND PROCESSES FOR PREPARING ALDEHYDES | EASTMAN CHEMICAL COMPANY (US) | 2013-12-05 | — | — | US | disclosed |
| WO-2013181186-A1 | CATALYSTS AND PROCESS FOR PRODUCING ALDEHYDES | EASTMAN CHEMICAL COMPANY (US) | 2013-12-05 | — | — | WO | disclosed |
| WO-2013181188-A1 | CATALYST AND METHOD HAVING IMPROVED SELECTIVITY TO ISOBUTYRALDEHYDE VIA CATLAYST INDUCTION | EASTMAN CHEMICAL COMPANY (US) | 2013-12-05 | — | — | WO | disclosed |
| US-20130324713-A1 | CATALYST AND METHOD HAVING SELECTIVITY TO ISOBUTYRALDEHYDE VIA CATALYST INDUCTION | EASTMAN CHEMICAL COMPANY (US) | 2013-12-05 | — | — | US | disclosed |
| US-8598226-B2 | Fused cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-12-03 | — | — | US | disclosed |
| US-20130267589-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2013-10-10 | — | — | US | disclosed |
| WO-2013128378-A1 | PHENYL ALKANOIC ACID DERIVATIVES AS GPR AGONISTS | Piramal Enterprises Limited (IN) | 2013-09-06 | — | — | WO | disclosed |
| US-20130217664-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2013-08-22 | — | — | US | disclosed |
| US-8513411-B2 | Tetrahydro-imidazo[1,5-α] pyrazine derivatives, preparation process and medicinal use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2013-08-20 | — | — | US | disclosed |
| WO-2013117645-A1 | IMIDAZO [4, 5 -C] PYRIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2013-08-15 | — | — | WO | disclosed |
| WO-2013117649-A1 | IMIDAZO [4, 5 -C] PYRIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2013-08-15 | — | — | WO | disclosed |
| US-8492430-B2 | Fused cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-23 | — | — | US | disclosed |
| WO-2013090703-A1 | COMPOSITIONS AND METHODS TO ATTRACT THE BROWN MARMORATED STINK BUG (BMSB), HALYOMORPHA HALYS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 2013-06-20 | — | — | WO | disclosed |
| WO-2013086229-A1 | BICYCLIC ARYL AND HETEROARYL SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| US-20130150339-A1 | Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors | AMGEN INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130137852-A1 | NOVEL COMPOUNDS AS DPP-IV INHIBITORS AND PROCESS FOR PREPARATION THEREOF | Cadila Corporate Campus (IN) | 2013-05-30 | — | — | US | disclosed |
| EP-2593426-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| WO-2013041106-A1 | SYSTEM PROVIDING CONTROLLED DELIVERY OF GASEOUS 11CO FOR CARBONYLATION REACTIONS IN THE PREPARATION OF RADIOPHARMACEUTICALS FOR PET IMAGING | AARHUS UNIVERSITET (DK) | 2013-03-28 | — | — | WO | disclosed |
| WO-2013023795-A1 | COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIB/IIIA AND THEIR USE FOR IMAGING OF THROMBI | PIRAMAL IMAGING SA (CH) | 2013-02-21 | — | — | WO | disclosed |
| EP-2543437-A2 | HOMOGENEOUS ASYMMETRIC HYDROGENATION CATALYST | Takasago International Corporation (JP) | 2013-01-09 | — | — | EP | disclosed |
| US-20130005962-A1 | PROCESS FOR THE SYNTHESIS OF DERIVATIVES OF 3-AMINO-TETRAHYDROFURAN-3-CARBOXYLIC ACID AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-03 | — | — | US | disclosed |
| EP-2041123-B9 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2013-01-02 | — | — | EP | disclosed |
| EP-2533644-A1 | DIAZENIUMDIOLATE CYCLOPENTYL DERIVATIVES | Merck Sharp & Dohme Corp. (US) | 2012-12-19 | — | — | EP | disclosed |
| WO-2012166420-A1 | PHOSPHORIC ACID SALTS OF SITAGLIPTIN | MERCK SHARP & DOHME CORP. (US) | 2012-12-06 | — | — | WO | disclosed |
| US-20120283222-A1 | HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE | AJINOMOTO CO., INC. (JP) | 2012-11-08 | — | — | US | disclosed |
| EP-2511271-A1 | HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE | AJINOMOTO CO., INC. (JP) | 2012-10-17 | — | — | EP | disclosed |
| EP-2493303-A1 | 2- [1-PHENYL-5-HYDROXY-4a-SUBSTITUTED-HEXAHYDROCYCLOPENTA [F]INDAZOL-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS | Merck Sharp & Dohme Corp. (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20120220766-A1 | TETRAHYDRO-IMIDAZO[1,5-alpha] PYRAZINE DERIVATIVES, PREPERATION PROCESS AND MEDICINAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-08-30 | — | — | US | disclosed |
| US-20120214847-A1 | 2-[1-PHENYL-5-HYDROXY-4a-SUBSTITUTED-HEXAHYDROCYCLOPENTA[F]INDAZOL-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS | MERCK SHARP & DOHME CORP. (US) | 2012-08-23 | — | — | US | disclosed |
| US-8207161-B2 | Tetrahydro-imidazo[1,5-α]pyrazine derivatives, preparation process and medicinal use thereof | JIANGSU HENGRUI MEDICINE CO. LTD. (CN) | 2012-06-26 | — | — | US | disclosed |
| WO-2012079583-A1 | SYSTEM PROVIDING CONTROLLED DELIVERY OF GASEOUS CO FOR CARBONYLATION REACTIONS | AARHUS UNIVERSITET (DK) | 2012-06-21 | — | — | WO | disclosed |
| EP-2431367-A2 | Fused cyclic compounds as GPR40 receptor modulators | Takeda Pharmaceutical Company Limited (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-20120046338-A1 | FUSED CYCLIC COMPOUNDS | YASUMA TSUNEO (JP) | 2012-02-23 | — | — | US | disclosed |
| EP-2415754-A2 | IMPROVED METHOD FOR MANUFACTURING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | Dong-A Pharmaceutical Co., Ltd. (KR) | 2012-02-08 | — | — | EP | disclosed |
| EP-2041123-B1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2012-02-01 | — | — | EP | disclosed |
| WO-2012007365-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | disclosed |
| US-20120010190-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-12 | — | — | US | disclosed |
| US-8088821-B2 | Fused cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20110201732-A1 | Method for Producing Dialkylphosphinic Acids and Esters and Salts Thereof by Means of Allyl Alcohols-Acroleins and use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-08-18 | — | — | US | disclosed |
| WO-2011100384-A1 | DIAZENIUMDIOLATE CYCLOPENTYL DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2011-08-18 | — | — | WO | disclosed |
| WO-2011053574-A1 | 2- [1-PHENYL-5-HYDROXY-4a-SUBSTITUTED-HEXAHYDROCYCLOPENTA [F] INDAZOL-5-YL] ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS | MERCK SHARP & DOHME CORP. (US) | 2011-05-05 | — | — | WO | disclosed |
| US-7910272-B2 | Dye-containing photosensitive composition, color filter using the same, and production method thereof | FUJIFILM CORPORATION (JP) | 2011-03-22 | — | — | US | disclosed |
| EP-1654263-B2 | PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR | MERCK SHARP & DOHME (US) | 2011-02-23 | — | — | EP | disclosed |
| US-20100317848-A1 | PROCESS FOR THE SYNTHESIS OF DERIVATIVES OF 3-AMINO-TETRAHYDROFURAN-3-CARBOXYLIC ACID AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-20100297724-A1 | METAL ENTRAPPED COMPOUNDS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2010-11-25 | — | — | US | disclosed |
| EP-2248812-A2 | Fused cyclic compounds as GPR40 receptor modulators | Takeda Pharmaceutical Company Limited (JP) | 2010-11-10 | — | — | EP | disclosed |
| EP-2099801-B1 | IMIDAZOÝ1,5-B¨PYRIDAZINAMIDO LIGANDS AND THEIR COMPLEXES | AIKAA CHEMICALS GMBH (DE) | 2010-11-03 | — | — | EP | disclosed |
| US-20100273786-A1 | TETRAHYDRO-IMIDAZ0[1,5-A]PYRAZINE DERIVATIVES, PREPARATION PROCESS AND MEDICINAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2010-10-28 | — | — | US | disclosed |
| WO-2010097420-A1 | PROCESS FOR THE PREPARATION OF A CHIRAL BETA AMINOACID DERIVATIVE AND INTERMEDIATES THEREOF | Esteve Química, S.A. (ES) | 2010-09-02 | — | — | WO | disclosed |
| EP-2223923-A1 | Process for the preparation of a chiral beta aminoacid derivative and intermediates thereof | Esteve Química, S.A. (ES) | 2010-09-01 | — | — | EP | disclosed |
| US-20100197761-A1 | Fused cyclic compounds | YASUMA TSUNEO | 2010-08-05 | — | — | US | disclosed |
| US-20100172825-A1 | Molecular Hydrogen Stores and Hydrogen Transfer Reagents for Hydrogenation Reactions | UNIVERSITAT HEIDELBERG (DE) | 2010-07-08 | — | — | US | disclosed |
| US-7732626-B2 | Fused cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-08 | — | — | US | disclosed |
| US-7714053-B2 | Rubber compound | CARL FREUDENBERG KG (DE) | 2010-05-11 | — | — | US | disclosed |
| EP-1807393-B1 | DIARYLSULFONES AS 5-HT2A ANTAGONISTS | MERCK SHARP & DOHME (GB) | 2010-03-31 | — | — | EP | disclosed |
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20090306037-A1 | Combination of a Dipeptidyl Peptidase-IV Inhibitor and a Cannabinoid CB1 Receptor Antagonist for the Treatment of Diabetes and Obesity | MERCK & CO., INC. (US) | 2009-12-10 | — | — | US | disclosed |
| EP-2114909-A2 | PROCESS FOR THE SYNTHESIS OF DERIVATIVES OF 3-AMINO-TETRAHYDROFURAN-3-CARBOXYLIC ACID AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2009-11-11 | — | — | EP | disclosed |
| US-7612072-B2 | Amorphous form of a phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor | MERCK & CO., INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090221592-A1 | Dodecylsulfate Salt Of A Dipeptidyl Peptidase-Iv Inhibitor | MERCK SHARP & DOHME CORP. | 2009-09-03 | — | — | US | disclosed |
| EP-1708571-A4 | NOVEL CRYSTALLINE SALTS OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR | MERCK & CO INC (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20090170824-A1 | Diarylsulfones as 5-HT2A Antagonists | CASTRO PINEIRO JOSE LUIS | 2009-07-02 | — | — | US | disclosed |
| US-20090156579-A1 | Combination of a Dipeptidyl Peptidase-4 Inhibitor and an Anti-Hypertensive Agent for the Treatment of Diabetes and Hypertension | MERCK SHARP & DOHME CORP. | 2009-06-18 | — | — | US | disclosed |
| EP-1879582-A4 | COMBINATION OF DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND A CANNABINOID CB1 RECEPTOR ANTAGONIST FOR THE TREATMENT OF DIABETES AND OBESITY | MERCK & CO INC (US) | 2009-05-13 | — | — | EP | disclosed |
| US-20090054397-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND | OHI NORIHITO | 2009-02-26 | — | — | US | disclosed |
| US-7495123-B2 | Process for the preparation of enantiomerically enriched beta amino acid derivatives | SOLVIAS AG (CH) | 2009-02-24 | — | — | US | disclosed |
| EP-1796671-A4 | AMORPHOUS FORM OF A PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR | MERCK & CO INC (US) | 2009-01-21 | — | — | EP | disclosed |
| EP-1667524-A4 | NOVEL CRYSTALLINE FORM OF A PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR | MERCK & CO INC (US) | 2009-01-14 | — | — | EP | disclosed |
| EP-1662876-A4 | NOVEL CRYSTALLINE FORMS OF A PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR | MERCK & CO INC (US) | 2009-01-14 | — | — | EP | disclosed |
| US-20080315148-A1 | Rubber Compound | CARL FREUDENBERG KG (DE) | 2008-12-25 | — | — | US | disclosed |
| US-7468459-B2 | Process for the preparation of chiral beta amino acid derivatives by asymmetric hydrogenation | MERCK & CO., INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7468393-B2 | Diarylsulfones as 5-HT2A antagonists | MERCK SHARP & DOHME LTD. (GB) | 2008-12-23 | — | — | US | disclosed |
| WO-2008127480-A2 | PACKED BED MICROREACTORS | CORNELL RESEARCH FOUNDATION, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| US-7429609-B2 | Pyrazole compound and medicinal composition containing the same | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-20080227786-A1 | Novel Crystalline Salts of a Dipeptidyl Peptidase-IV Inhibitor | FERLITA RUSSELL R | 2008-09-18 | — | — | US | disclosed |
| EP-1942921-A2 | COMBINATION OF A DIPEPTIDYL PEPTIDASE-4 INHIBITOR AND AN ANTI-HYPERTENSIVE AGENT FOR THE TREATMENT OF DIABETES AND HYPERTENSION | Merck & Co., Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| WO-2008080891-A2 | PROCESS FOR THE SYNTHESIS OF DERIVATIVES OF 3-AMINO-TETRAHYDROFURAN-3-CARBOXYLIC ACID AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-10 | — | — | WO | disclosed |
| EP-1606243-B1 | PROCESS FOR THE PREAPAATION OF CHIRAL BETA AMINO ACID DERIVATIVES BY ASYMMETRIC HYDROGENATION | MERCK & CO INC (US) | 2008-07-09 | — | — | EP | disclosed |
| US-20080091040-A1 | Optically active alkenylphosphinic acid ester and process for producing the same | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2008-04-17 | — | — | US | disclosed |
| US-20080058522-A1 | Process For The Preparation Of Enantiomerically Enriched Beta Amino Acid Derivatives | MERCK SHARP & DOHME LLC | 2008-03-06 | — | — | US | disclosed |
| US-7326708-B2 | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor | MERCK & CO., INC. (US) | 2008-02-05 | — | — | US | disclosed |
| EP-1879582-A2 | COMBINATION OF DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND A CANNABINOID CB1 RECEPTOR ANTAGONIST FOR THE TREATMENT OF DIABETES AND OBESITY | Merck & Co., Inc. (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20070281941-A1 | Amorphous Form of a Phosphoric Acid Salt of a Dipeptidyl Peptidase-IV Inhibitor | MERCK SHARP & DOHME LLC | 2007-12-06 | — | — | US | disclosed |
| EP-1856028-A1 | PROCESS TO CHIRAL BETA AMINO ACID DERIVATIVES BY ASYMMETRIC HYDROGENATION | Merck & Co., Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| EP-1654263-B1 | PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR | MERCK & CO INC (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20070203205-A1 | Diarylsulfones as 5-HT2A antagonists | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2007-08-30 | — | — | US | disclosed |
| US-20070190435-A1 | Dye-containing photosensitive composition, color filter using the same, and production method thereof | FUJIFILM CORPORATION (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20070184366-A1 | DYE CONTAINING CURABLE COMPOSITION, COLOR FILTER, AND PROCESS OF PREPARING COLOR FILTER | FUJIFILM CORPORATION | 2007-08-09 | — | — | US | disclosed |
| EP-1807393-A1 | DIARYLSULFONES AS 5-HT2A ANTAGONISTS | Merck Sharp & Dohme Limited (GB) | 2007-07-18 | — | — | EP | disclosed |
| EP-1796671-A1 | AMORPHOUS FORM OF A PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR | Merck & Co., Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| US-7217740-B2 | Diarylsulfones as 5-HT2A antagonists | MERCK SHARP AND DOHME | 2007-05-15 | — | — | US | disclosed |
| US-20070099096-A1 | Dye-containing curable composition, color filter and method of producing thereof | FUJIFILM CORPORATION | 2007-05-03 | — | — | US | disclosed |
| WO-2007050485-A2 | COMBINATION OF A DIPEPTIDYL PEPTIDASE-4 INHIBITOR AND AN ANTI-HYPERTENSIVE AGENT FOR THE TREATMENT OF DIABETES AND HYPERTENSION | MERCK & CO., INC. (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20070021430-A1 | Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor | MERCK & CO., INC. | 2007-01-25 | — | — | US | disclosed |
| EP-1735269-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED BETA AMINO ACID DERIVATIVES | Merck & Co., Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20060287528-A1 | Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor | MERCK & CO., INC. | 2006-12-21 | — | — | US | disclosed |
| US-20060270722-A1 | Combination of a dipeptidyl peptidase-IV inhibitor and a dual PPAR agonist for the treatment of diabetes and obesity | THORNBERRY NANCY A | 2006-11-30 | — | — | US | disclosed |
| WO-2006119260-A2 | COMBINATION OF DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND A CANNABINOID CB1 RECEPTOR ANTAGONIST FOR THE TREATMENT OF DIABETES AND OBESITY | MERCK & CO., INC. (US) | 2006-11-09 | — | — | WO | disclosed |
| EP-1708571-A1 | NOVEL CRYSTALLINE SALTS OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR | Merck & Co., Inc. (US) | 2006-10-11 | — | — | EP | disclosed |
| EP-1375505-B1 | OPTICALLY ACTIVE ALKENYLPHOSPHINIC ACID ESTER AND PROCESS FOR PRODUCING THE SAME | JAPAN SCIENCE & TECH AGENCY (JP) | 2006-09-13 | — | — | EP | disclosed |
| US-20060194977-A1 | Process for the preparation of chiral beta amino acid derivatives by asymmetric hydrogenation | MERCK SHARP & DOHME LLC | 2006-08-31 | — | — | US | disclosed |
| WO-2006081151-A1 | PROCESS TO CHIRAL BETA AMINO ACID DERIVATIVES BY ASYMMETRIC HYDROGENATION | MERCK & CO., INC. (US) | 2006-08-03 | — | — | WO | disclosed |
| EP-1667524-A2 | NOVEL CRYSTALLINE FORM OF A PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR | Merck & Co., Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2006060225-A2 | PROCESS FOR ASYMMETRIC SYNTHESIS OF HEXAHYDROPYRIMIDO[1,2-A] AZEPINE-2-CARBOXAMIDES AND RELATED COMPOUNDS | MERCK & CO., INC. (US) | 2006-06-08 | — | — | WO | disclosed |
| EP-1662876-A2 | NOVEL CRYSTALLINE FORMS OF A PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR | Merck & Co., Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-1654263-A1 | PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR | Merck & Co., Inc. (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2006034512-A2 | PHENYL-SUBSTITUTED QUINOLINE AND QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF DIABETES | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-03-30 | — | — | WO | disclosed |
| WO-2006034491-A2 | PHENYL-SUBSTITUTED QUINOLINE AND QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF DIABETES | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-03-30 | — | — | WO | disclosed |
| WO-2006033848-A1 | AMORPHOUS FORM OF A PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR | MERCK & CO., INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060052445-A1 | Diarylsulfones as 5-HT2A antagonists | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2006-03-09 | — | — | US | disclosed |
| WO-2006021805-A1 | DIARYLSULFONES AS 5-HT2A ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2006-03-02 | — | — | WO | disclosed |
| EP-1606243-A1 | PROCESS FOR THE PREAPAATION OF CHIRAL BETA AMINO ACID DERIVATIVES BY ASYMMETRIC HYDROGENATION | Merck & Co. Inc. (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
| WO-2005097733-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED BETA AMINO ACID DERIVATIVES | MERCK & CO., INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| US-6949667-B2 | Alkenylphosphonic ester and preparation process thereof | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2005-09-27 | — | — | US | disclosed |
| US-20050208582-A1 | Pyrazole compounds and pharmaceutical compositions comprising the compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-09-22 | — | — | US | disclosed |
| US-6930189-B2 | Chiral ligand | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-08-16 | — | — | US | disclosed |
| WO-2005072530-A1 | NOVEL CRYSTALLINE SALTS OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR | MERCK & CO., INC. (US) | 2005-08-11 | — | — | WO | disclosed |
| WO-2005030127-A2 | NOVEL CRYSTALLINE FORM OF A PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR | MERCK & CO., INC. (US) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005020920-A2 | NOVEL CRYSTALLINE FORMS OF A PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR | MERCK & CO., INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| EP-1510516-A1 | PYRAZOLE COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2005-03-02 | — | — | EP | disclosed |
| US-20050032804-A1 | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor | MERCK SHARP & DOHME LLC | 2005-02-10 | — | — | US | disclosed |
| WO-2005003135-A1 | PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR | MERCK & CO., INC. (US) | 2005-01-13 | — | — | WO | disclosed |
| EP-1487827-A1 | ANTI-INFLAMMATORY MORPHOLIN-ACETAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2004-12-22 | — | — | EP | disclosed |
| WO-2004085378-A1 | PROCESS FOR THE PREPARATION OF CHIRAL BETA AMINO ACID DERIVATIVES BY ASYMMETRIC HYDROGENATION | MERCK & CO. INC. (US) | 2004-10-07 | — | — | WO | disclosed |
| US-20040185372-A1 | Dye-containing curable composition, color filter, and process of preparing color filter | FUJI PHOTO FILM CO., LTD. | 2004-09-23 | — | — | US | disclosed |
| US-6765107-B2 | SIMPLE, HIGH YEILD CATALYTIC REACTION OF ALKENE AND HYDRIDO-PHOSPHONATE DERIVATIVE | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2004-07-20 | — | — | US | disclosed |
| US-6762306-B2 | A N,O-BIS(DIPHENYLPHOSPHINO)-2-AZETIDINE DERIVATIVES, A TRANSITION METAL COMPLEX FOR USE AS HYDROGENATION CATALYSTS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-07-13 | — | — | US | disclosed |
| US-20040110965-A1 | Chiral ligand | SUMITOMO CHEMICAL COMPANY, LIMITED | 2004-06-10 | — | — | US | disclosed |
| US-20040092752-A1 | Optically active alkenylphosphinic acid esters and process for producing the same | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2004-05-13 | — | — | US | disclosed |
| US-20030191324-A1 | Chiral ligand | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-10-09 | — | — | US | disclosed |
| WO-2003082862-A1 | ANTI-INFLAMMATORY MORPHOLIN-ACETAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-10-09 | — | — | WO | disclosed |
| US-20030166612-A1 | Alkenylphosphonic ester and preparation process thereof | TANAKA, MASATO (JP) | 2003-09-04 | — | — | US | disclosed |
| WO-2003072247-A1 | ORGANOMETALLIC CATALYST IMMOBILIZED ON MAGNETIC NANOPARTICLE AND PROCESS FOR THE PRODUCTION THEREOF | FAR EAST ASIA CORPORATION (KR) | 2003-09-04 | — | — | WO | disclosed |
| EP-0942010-B1 | Transition metal compounds, catalyst components and catalysts for olefin polymerization, and process for producing olefinic polymer | SUMITOMO CHEMICAL CO (JP) | 2003-06-18 | — | — | EP | disclosed |
| US-6500909-B2 | CONTAINING NICKEL, PALLADIUM, RHODIUM, RUTHENIUM, OR COBALT | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-12-31 | — | — | US | disclosed |
| US-20020188160-A1 | The catalyst either water-soluble or carbon dioxide-soluble and the reaction product soluble in the phase in which the catalyst is insoluble, wherein the reaction products and catalyst can be readily separated by a phase separation | LOS ALAMOS NATIONAL SECURITY, LLC | 2002-12-12 | — | — | US | disclosed |
| EP-1241174-A1 | Chiral ligands for asymmetric synthesis | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-09-18 | — | — | EP | disclosed |
| EP-1174426-A1 | METHOD FOR THE PREPARATION OF TRICYCLIC AMINO ALCOHOL DERIVATIVES THROUGH AZIDES | Asahi Kasei Kabushiki Kaisha (JP) | 2002-01-23 | — | — | EP | disclosed |
| US-20010027162-A1 | Transition metal compound, catalyst component for olefin polymerization, catalyst for olefin polymerization, and process for producing olefinic polymer | HIRAHATA WATARU (JP) | 2001-10-04 | — | — | US | disclosed |
| US-6242377-B1 | POLYMERIZATION IN PRESENCE OF BISOXAZOLINE WITH NICKEL, COBALT, PALLADIUM, RHODIUM, RUTHENIUM, ALUMINUM AND BORON COMPLEXES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-06-05 | — | — | US | disclosed |
| US-6025524-A | CATALYTIC AMINATION IN THE PRESENCE OF A CATALYST, WHICH IS DISSOLVED OR SUSPENDED IN WATER | HOECHST RESEARCH & TECHNOLOGY DEUTSCHLAND GMBH & CO. KG (DE) | 2000-02-15 | — | — | US | disclosed |
| EP-0942010-A1 | Transition metal compounds, catalyst components and catalysts for olefin polymerization, and process for producing olefinic polymers | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-09-15 | — | — | EP | disclosed |
| US-5858905-A | Pyrophosphite ligands and their use in transition metal catalyzed processes | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 1999-01-12 | — | — | US | disclosed |
| US-5817850-A | Ferrocene bis(phosphonite) ligands and complexes for transition-metal-catalyzed reactions | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 1998-10-06 | — | — | US | disclosed |
| US-5684185-A | MULTISTAGE REACTION OF SULFIDING, REACTION WITH YLIDE, HYDROLYSIS, HYDROGENATION AND OXIDATION | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-11-04 | — | — | US | disclosed |
| US-5442015-A | Aldehyde-telechelic polyisobutylenes, catalytic method for preparing the same with high conversion and selectivity, and block copolymers made therefrom | THE UNIVERSITY OF AKRON | 1995-08-15 | — | — | US | disclosed |
| EP-0228095-B1 | PROCESS FOR THE PREPARATION OF OLEFINIC SILANES AND SILOXANES | UNION CARBIDE CORPORATION (US) | 1992-01-22 | — | — | EP | disclosed |
| EP-0274076-B1 | ACID ACCELERATED HYDROCARBOXYLATION | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-10-09 | — | — | EP | disclosed |
| US-4889957-A | HYDROFORMYLATION OF UNSATURATED HYDROCARBONS | RHONE-POULENC CHIMIE DE BASE (FR) | 1989-12-26 | — | — | US | disclosed |
| EP-0181003-B1 | HYDROCARBOXYLATION OF BUTADIENE TO 3-PENTENOIC ACID | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-10-25 | — | — | EP | disclosed |
| US-4788334-A | Acid accelerated hydrocarboxylation | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-11-29 | — | — | US | disclosed |
| US-4778905-A | WITH SULFONATED TRIARYLPHOSPHINE LIGAND | RHONE-POULENC CHIMIE DE BASE (FR) | 1988-10-18 | — | — | US | disclosed |
| EP-0274076-A2 | Acid accelerated hydrocarboxylation | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-07-13 | — | — | EP | disclosed |
| EP-0228095-A2 | Process for the preparation of olefinic silanes and siloxanes | UNION CARBIDE CORPORATION (US) | 1987-07-08 | — | — | EP | disclosed |
| US-4668812-A | Process for the preparation of olefinic silanes and siloxanes | UNION CARBIDE CORPORATION (US) | 1987-05-26 | — | — | US | disclosed |
| US-4622423-A | RHODIUM CATALYST, IODIDE PROMOTER | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1986-11-11 | — | — | US | disclosed |
| EP-0181003-A2 | Hydrocarboxylation of butadiene to 3-pentenoic acid | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1986-05-14 | — | — | EP | disclosed |
| US-4111952-A | Process for preparing lower lactams from allylic amine substrates | TEXACO INC. (US) | 1978-09-05 | — | — | US | disclosed |
| US-4110340-A | Process for preparing lower lactams from allylic halide substrates | TEXACO INC. (US) | 1978-08-29 | — | — | US | disclosed |
| US-4110340-A | Process for preparing lower lactams from allylic halide substrates | TEXACO INC. (US) | 1978-08-29 | — | — | US | disclosed |